Sort   by:  
 Page size 
TranscriptomicsmRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer
The intention was to detect genes that are determining trastuzumab efficiency in HER2-positive breast cancer cell lines with different resistance phenotypes. While BT474 should be sensitive to the drug treatment, HCC1954 is expected to be resistant due to a PI3K mutation. The cell line BTR50 has bee...
ORGANISM(S): Homo sapiens 
2015-04-21 | E-GEOD-55005 | biostudies-arrayexpress
Transcriptomics03-311 Trastzumab preoperative Trial of Early Stage HER2+ BRCA
Tumor core biopsies were obtained at baseline and after brief-exposure to single-agent trastuzumab from patients enrolled on the 03-311 trial. Gene expression profiling was conducted on these tumor biopsies to identify signatures of response to preoperative therapy. This study was initiated to ide...
ORGANISM(S): Homo sapiens 
2016-02-09 | E-GEOD-76360 | biostudies-arrayexpress
TranscriptomicsDefining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
The purpose of this study was to characterise the effects of trastuzumab and pertuzumab, either as single agents or as combination therapy on gene and protein expression in human ovarian cancer in vivo. Illumina BeadChips were used to profile the transcriptome after four days treatment of SKOV3 tumo...
ORGANISM(S): Homo sapiens 
2012-05-02 | E-GEOD-31432 | biostudies-arrayexpress
TranscriptomicsTrastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells
Objective: Trastuzumab has been used for the treatment of HER2-positive breast cancer (BC). However, a subset of BC patients exhibited resistance to trastuzumab therapy. Thus, clarifying the molecular mechanism of trastuzumab treatment will be beneficial to improve the treatment of HER2-positive BC ...
ORGANISM(S): Homo sapiens 
2012-06-02 | E-GEOD-38415 | biostudies-arrayexpress
TranscriptomicsHER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib
HER2 targeting with trastuzumab has changed the prognosis of breast cancer patients carrying amplification and/or overexpression of this oncogene. Despite this progress, however, resistance to trastuzumab occurs in the vast majority of patients. Newer anti-HER2 therapies, like the dual tyrosine-kina...
ORGANISM(S): Homo sapiens 
2010-12-15 | E-GEOD-17630 | biostudies-arrayexpress
MetabolomicsMass spectroscopy‑based proteomics and metabolomics analysis of triple‑positive breast cancer cells treated with trastuzumab
Not available
ORGANISM(S): Homo sapiens 
ST002318 | MetabolomicsWorkbench
TranscriptomicscaArray_harri-00137: Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer
To assess pathologic complete response (pCR), clinical response, feasibility, safety, and potential predictors of response to preoperative trastuzumab plus vinorelbine in patients with operable, human epidermal growth factor receptor 2 (HER2)-positive breast cancer. EXPERIMENTAL DESIGN: 48 patients ...
ORGANISM(S): Homo sapiens 
2015-06-25 | E-GEOD-70233 | biostudies-arrayexpress
TranscriptomicsHuman breast cancer SKBr-3 cells: trastuzumab-resistant vs. parental
Human breast cancer SKBr-3 cells selected with trastuzumab for 6 month compared with parental SKBr-3 cells; Goal was to screen for microRNAs involved in development of trastuzumab resistance. Human breast cancer SKBr-3 cells were continuously cultured in the presence ofM-BM- 5M-BM-5g/ml trastuzumab...
ORGANISM(S): Homo sapiens 
2013-05-25 | E-GEOD-47011 | biostudies-arrayexpress
TranscriptomicsClinical and Pathologic Response of the Primary Tumor in Women Receiving Neoadjuvant Docetaxel-Capecitabine (+/- Trastuzumab) Chemotherapy
Results: In subjects who completed treatment and surgery, the pCR and near-complete response rates were 15.8% in HER2-negative and 50% in HER2-positive subjects. When stratified by genomic subtype, subjects of the HER2-enriched subtype had the best response (66.7%), the luminal A (11%) and B (4.8%) ...
ORGANISM(S): Homo sapiens 
2011-03-18 | E-GEOD-22358 | biostudies-arrayexpress
TranscriptomicsTreatment effects of trastuzumab and TDM-1 in a murine model of breast cancer brain metastasis
Background: Central nervous system (CNS) metastases represent a major problem in the treatment of HER2-positive breast cancer due to the disappointing efficacy of HER2-targeted therapies in the brain microenvironment. The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has shown efficacy i...
ORGANISM(S): Homo sapiens 
2015-11-09 | E-GEOD-69042 | biostudies-arrayexpress
Sort   by:  
 Page size